1001 related articles for article (PubMed ID: 2934543)
1. Pharmacological, hemodynamic and biochemical mechanisms involved in the blood pressure lowering effects of pergolide, in normotensive and hypertensive dogs.
Cavero I; Lorrain J; Di Paola ED; Lhoste F; Payen B; Dennis T; Scatton B
J Pharmacol Exp Ther; 1985 Dec; 235(3):798-809. PubMed ID: 2934543
[TBL] [Abstract][Full Text] [Related]
2. Pharmacological, hemodynamic and autonomic nervous system mechanisms responsible for the blood pressure and heart rate lowering effects of pergolide in rats.
Cavero I; Lefevre-Borg F; Lhoste F; Sabatier C; Richer C; Giudicelli JF
J Pharmacol Exp Ther; 1984 Mar; 228(3):779-91. PubMed ID: 6707926
[TBL] [Abstract][Full Text] [Related]
3. Central and peripheral dopaminergic mechanisms in the cardiovascular actions of pergolide in neurogenic hypertensive dogs.
Barrett RJ; Lokhandwala MF
Eur J Pharmacol; 1983 Dec; 96(3-4):211-26. PubMed ID: 6676105
[TBL] [Abstract][Full Text] [Related]
4. Functional and biochemical evidence for the lack of cardiac presynaptic alpha-2 adrenoceptor stimulant properties of cirazoline (LD 3098), a potent alpha-1 adrenoceptor agonist in dogs and rats.
Cavero I; Lefèvre-Borg F; Roach AG; Gomeni R; Scatton B
J Pharmacol Exp Ther; 1982 Oct; 223(1):241-50. PubMed ID: 6126583
[TBL] [Abstract][Full Text] [Related]
5. Characterization of the neurogenic vasodilatation elicited by central dopamine receptor stimulation with pergolide.
Lokhandwala MF; Kivlighn SD; Jandhyala BS
J Pharmacol Exp Ther; 1984 Mar; 228(3):696-703. PubMed ID: 6707919
[TBL] [Abstract][Full Text] [Related]
6. Blood pressure lowering effects of N,N-di-n-propyl-dopamine in rats: evidence for stimulation of peripheral dopamine receptors leading to inhibition of sympathetic vascular tone.
Cavero I; Lefèvre-Borg F; Gomeni R
J Pharmacol Exp Ther; 1981 Aug; 218(2):515-24. PubMed ID: 7252851
[TBL] [Abstract][Full Text] [Related]
7. Effects of pergolide, a dopamine receptor agonist, and clonidine on cardiovascular responses evoked by activation of peripheral sympathetic outflow in rats.
Cavero I
Clin Exp Hypertens A; 1982; 4(1-2):221-33. PubMed ID: 7074987
[TBL] [Abstract][Full Text] [Related]
8. Urethane inhibits cardiovascular responses mediated by the stimulation of alpha-2 adrenoceptors in the rat.
Armstrong JM; Lefèvre-Borg F; Scatton B; Cavero I
J Pharmacol Exp Ther; 1982 Nov; 223(2):524-35. PubMed ID: 6127404
[TBL] [Abstract][Full Text] [Related]
9. Effects of pergolide on the cardiovascular responses to sinoaortic deafferentation in dogs with intact or surgically decentralized adrenal glands.
Lorrain J; Donato Di Paola E; Lhoste F; Cavero I
J Pharmacol Exp Ther; 1987 Jan; 240(1):288-93. PubMed ID: 3806390
[TBL] [Abstract][Full Text] [Related]
10. Effects of cerebroventricular administration of ouabain on renal hemodynamics in anesthetized dogs: evidence for the participation of renal dopaminergic vasodilator fibers.
Hom GJ; Jandhyala BS
J Pharmacol Exp Ther; 1984 Aug; 230(2):275-83. PubMed ID: 6747837
[TBL] [Abstract][Full Text] [Related]
11. Presynaptic dopamine receptor stimulation in the cardiovascular actions of lergotrile.
Barrett RJ; Lokhandwala MF
J Pharmacol Exp Ther; 1981 Jun; 217(3):660-5. PubMed ID: 6112262
[TBL] [Abstract][Full Text] [Related]
12. Systemic hemodynamic and regional blood flow effects of LY141865, a selective dopamine receptor agonist.
Hahn RA; MacDonald BR
J Pharmacol Exp Ther; 1984 Sep; 230(3):558-68. PubMed ID: 6470973
[TBL] [Abstract][Full Text] [Related]
13. Cardiovascular pharmacology of ASL-7022. III. Peripheral vascular adrenergic mechanisms.
Gorczynski RJ; Reynolds RD
J Pharmacol Exp Ther; 1985 Mar; 232(3):629-35. PubMed ID: 2857783
[TBL] [Abstract][Full Text] [Related]
14. Analysis of the cardiovascular effects of co-derocrine (Hydergine).
Clark BJ; Bucher T; Waite R
J Pharmacol; 1985; 16 Suppl 3():101-11. PubMed ID: 2869189
[TBL] [Abstract][Full Text] [Related]
15. Pharmacological characterization of alpha adrenoceptors involved in the antinociceptive and cardiovascular effects of intrathecally administered clonidine.
Solomon RE; Brody MJ; Gebhart GF
J Pharmacol Exp Ther; 1989 Oct; 251(1):27-38. PubMed ID: 2571720
[TBL] [Abstract][Full Text] [Related]
16. Effect of quinpirole, a specific dopamine DA2 receptor agonist on the sympathoadrenal system in dogs.
Damase-Michel C; Montastruc JL; Gharib C; Geelen G; De Saint-Blanquat G; Tran MA
J Pharmacol Exp Ther; 1990 Feb; 252(2):770-7. PubMed ID: 1968975
[TBL] [Abstract][Full Text] [Related]
17. Cardiovascular characterization of the DA2 dopamine receptor agonist quinpirole in rats.
Lefevre-Borg F; Lorrain J; Lechaire J; Thiry C; Lhoste F; Hicks PE; Cavero I
Fundam Clin Pharmacol; 1987; 1(3):179-200. PubMed ID: 2892767
[TBL] [Abstract][Full Text] [Related]
18. Primate cardiovascular responses mediated by dopamine receptors: effects of N,N-di-n-propyldopamine and LY171555.
Hahn RA; MacDonald BR
J Pharmacol Exp Ther; 1984 Apr; 229(1):132-8. PubMed ID: 6707929
[TBL] [Abstract][Full Text] [Related]
19. Hemodynamic and pharmacological evaluation of the vasodilator and vasoconstrictor effects of endothelin-1 in rats.
Le Monnier de Gouville AC; Mondot S; Lippton H; Hyman A; Cavero I
J Pharmacol Exp Ther; 1990 Jan; 252(1):300-11. PubMed ID: 2405151
[TBL] [Abstract][Full Text] [Related]
20. The cardiovascular effects of the antihypertensive drug debrisoquin: a contribution to the pharmacology of chronic treatment. I. One-week administration to dogs.
Cavero I; Gerold M; Saner A; Haeusler G
J Pharmacol Exp Ther; 1978 Jul; 206(1):123-31. PubMed ID: 660542
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
